Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma - 04/04/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | UDP-glucuronosyltransferases play an important role in lung cancer progression. |
• | Hesperetin has made progress in anti-tumor treatment. |
• | Hesperetin synergizes platinum drugs exhibit a more obvious inhibitory effect on lung cancer progression. |
Abstract |
Lung cancer remains the leading cause of oncological death. There is an urgent need to discover new molecular targets and to develop new treatments. One of the UDP-glucuronosyltransferases (UGTs) family, UGT1A3, is highly expressed in lung adenocarcinoma (LUAD), and is associated with poor prognosis. Its inhibitor, hesperetin, may play an important role in anticancer therapy. The purpose of this study was to investigate the role of UGT1A3 in the progression of lung adenocarcinoma and to explore the value of its inhibitor hesperetin in the treatment of LUAD. Hesperetin suppressed lung adenocarcinoma cell proliferation and migration. The combination treatment of hesperetin with platinum suppressed tumor progression more significantly, especially compared with single drug treatment. UGT1A3 is an important prognostic factor for LUAD, and hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS).
Le texte complet de cet article est disponible en PDF.Abbreviations : NSCLC, UGTs, LUAD, TCGA, FBS, SRB, ROS, LDLr, BSA
Keywords : Lung cancer, Hesperetin, UDP-glucuronosyltransferases
Plan
Vol 113
Article 108779- mai 2019 Retour au numéro
Article précédent
- Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways
- Yu Zhang, Ling Zhang, Xiaoxue Fan, Weiwei Yang, Boyang Yu, Junping Kou, Fang Li
- IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma
- Xing Zhang, Runchen Miao, Tian Liu, Xiaohong Xiang, Jingxian Gu, Yifan Jia, Zeyu Li, Yunong Fu, Yang He, Yuhua Zhang, Jingyao Zhang, Kai Qu, Chang Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?